Corentec Co

Corentec Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Corentec Co (104540.KQ) as of Nov 20, 2026 is 365.25 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 492.78 % — a change of -25.88% (lower).

FCF Conversion

365.25 %

YoY

-25.88%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Corentec Co is 2025 365.25 % . FCF Conversion Rate (FCF/EBITDA) of Corentec Co was 2024 492.78 % . It decreases by -25.88% lower compared to the previous year.

The Corentec Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-4.39 KRW
Jan 1, 2019
22.30 KRW
Jan 1, 2020
-635.45 KRW
Jan 1, 2021
-564.34 KRW
Jan 1, 2022
249.65 KRW
Jan 1, 2023
-226.70 KRW
Jan 1, 2024
492.78 KRW
Jan 1, 2025
365.25 KRW
The Corentec Co FCF Conversion history
YEARFCF ConversionYoY
365.25 %-25.88%
492.78 %-317.38%
-226.70 %-190.80%
249.65 %-144.24%
-564.34 %-11.19%
-635.45 %-2,949.15%
22.30 %-607.69%
-4.39 %-103.98%
110.42 %-105.72%
-1,931.82 %-677.58%
334.47 %+1.53%
329.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Corentec Co Stock analysis

What does Corentec Co do? Corentec Co., Ltd. manufactures and sells artificial articulations, including hip, knee, and spine products. The company offers hip products under the BENCOX brand, featuring primary systems, hemi-arthroplasty systems, and revision systems such as cementless femoral stems and acetabular cups. Knee products are sold under the LOSPA brand, including fixed and mobile primary knee systems and revision systems. Spine products also carry the LOSPA IS brand, comprising pedicle screws and peek cages. Corentec distributes these products domestically and internationally, targeting healthcare providers and hospitals that require orthopedic solutions. The firm’s revenue comes from the sale of hip, knee, and spine products through its BENCOX, LOSPA, and LOSPA IS brand portfolios. Domestic and overseas markets are key segments, with the company focusing on orthopedic surgeons and medical institutions that purchase these specialized medical devices. Corentec’s product lines are designed for both primary and revision surgeries, catering to a broad range of orthopedic needs in the healthcare sector. Corentec Co., Ltd. serves healthcare providers globally, with its BENCOX brand dominating hip product sales and LOSPA/LOSPA IS covering knee and spine solutions. The company’s distribution strategy emphasizes direct sales to hospitals and medical centers, ensuring consistent product availability for surgical procedures. By maintaining distinct brand identities for each product category, Corentec efficiently targets specific medical specialties within the orthopedic market. Corentec Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Corentec Co stock

FCF Conversion Rate (FCF/EBITDA) of Corentec Co is 365.25 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Corentec Co changed from 492.78 % to 365.25 %, representing a -25.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Corentec Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Corentec Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Corentec Co

All Key Metrics — Corentec Co